We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

QUIDEL

Develops, manufactures and markets rapid diagnostic tests at the point-ofcare (POC) that focus on infectious diseases... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

YKL-40 Associated with Severity in Patients with Necrotizing Soft-Tissue Infection

By LabMedica International staff writers
Posted on 28 Oct 2021
Print article
Image: Histopathological features of necrotizing fasciitis; light micrograph of a section of infected skin showing an extensive acute inflammatory reaction with associated intravascular thrombosis and necrosis (Photo courtesy of Dr. Steve Gschmeissner/Science Photo Library)
Image: Histopathological features of necrotizing fasciitis; light micrograph of a section of infected skin showing an extensive acute inflammatory reaction with associated intravascular thrombosis and necrosis (Photo courtesy of Dr. Steve Gschmeissner/Science Photo Library)
Necrotizing soft-tissue infection (NSTI) is a rare, severe and fast-progressing bacterial infection. NSTI can be caused by a myriad of aerobic, anaerobic and facultative anaerobic bacteria, but predominantly by Group A Streptococcus in monomicrobial infections.

YKL-40, also called chitinase-3-like-1 protein, may be an attractive prognostic biomarker in NSTI. YKL-40 is an acute phase protein secreted by several of immune cells, including macrophages, neutrophils and endothelial cells. Proteomic analysis has indicated YKL-40 as a promising biomarker in patients with severe sepsis and septic shock.

Clinical Scientists at the Copenhagen University Hospital (Copenhagen, Denmark) investigated the association between plasma YKL-40 and 30-day mortality in patients with NSTI, and assessed its value as a marker of disease severity. They determined plasma YKL-40 levels in 161 patients with NSTI and 65 age-sex matched controls upon admission and at day 1, 2 and 3.

Patient had blood samples collected into ethylenediaminetetraacetic acid (EDTA) sample tubes upon admission (baseline), and at the following three days (all between 8 AM and 12 AM). Plasma YKL-40 was quantified in duplicates by commercial enzyme-linked immunosorbent (ELISA) technique (Quidel, San Diego, CA, USA) at each of the four time points. The minimal detectable limit for YKL-40 was 10 ng/mL.

The investigators reported that baseline plasma YKL-40 was 1,191 ng/mL in patients with NSTI compared with 40 ng/mL in controls. YKL-40 was found to be significantly higher in patients with septic shock (1,942 versus 720 ng/mL), and in patients receiving renal-replacement therapy (2,382 versus 1,041 ng/mL). YKL-40 correlated with Simplified Acute Physiology Score II. Baseline YKL-40 above 1,840 ng/mL was associated with increased risk of 30-day mortality in age-sex-comorbidity adjusted analysis (OR 3.77), but after further adjustment for Simplified Acute Physiology Score II no association was found between YKL-40 and early mortality.

Plasma YKL-40 was significantly higher in patients with NSTI compared to controls at admission, and at day 1 and 2. Plasma YKL-40 at admission was significantly higher among 45 patients infected with mono or polymicrobial Group A Streptococcus in blood and/or tissue (2,338 ng/mL) compared to 104 other types of NSTI (1,246 ng/mL). However, this was not observed at day 1, 2 and 3. No microbial findings were observed in 12 patients.

The authors concluded that high plasma YKL-40 levels were associated with disease severity and risk of death in patients with NSTI. However, YKL-40 is not an independent predictor for 30-day mortality. The study was published on October 9, 2021 in the journal BMC Infectious Diseases.

Related Links:
Copenhagen University Hospital
Quidel



Gold Supplier
HAI Assay Quality Control
Amplichek II
New
Hemoglobin A1c Control
HbA1c (Auto)
New
β-hCG Test
RAMP TOTAL β-hCG Test
New
Portable Molecular Workstation
iPonatic III

Print article
IIR Middle East

Channels

Technology

view channel
Image: OneDraw Blood Collection Device significantly reduces obstacles for drawing blood (Photo courtesy of Drawbridge Health)

Near Pain-Free Blood Collection Technology Enables High-Quality Testing

Blood tests help doctors diagnose diseases and conditions such as cancer, diabetes, anemia, and coronary heart disease, as well as evaluate organ functionality. They can also be used to identify disease... Read more

Industry

view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.